Precipio Q3 2026 revenue rises 8% to $7 million
Management said it believes Precipio is well positioned to accelerate commercialization of existing products and pursue longer-term growth opportunities.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Precipio, Inc. (PRPO) reported third-quarter 2026 revenue of $7 million, up 8% year over year from $6 million. Product revenue was $1 million, and pathology revenue was $6 million.
The reconciliation reported adjusted EBITDA of $0.4 million, compared with $0.5 million in Q3 2025; EBITDA was $0.3 million in both periods. GAAP net income was $0.0 million, versus a $0.1 million net loss a year earlier. Quarter-end cash was more than $3.5 million. CEO Ilan Danieli said Precipio believes it is well positioned to accelerate commercialization of existing products and pursue longer-term growth opportunities.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Positive
- Moderate pointQuarterly revenue reached $7 million, up 8% year over year.
Negative
- Moderate pointAdjusted EBITDA fell to $0.4 million from $0.5 million in Q3 2025.
8-K Event Classification
Key Figures
Key Terms
Adjusted EBITDA financial
non-GAAP financial measure financial
Amortization of intangibles financial
Stock-based compensation expense financial
Earnings Snapshot
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What was PRPO's revenue in Q3 2026?
What was PRPO's adjusted EBITDA in Q3 2026?
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D. C. 20549
FORM
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE
ACT OF 1934
Date of report (Date of earliest event reported):
(Exact Name of Registrant as Specified in Its Charter)
(State of Incorporation) |
(Commission File Number) | (I.R.S. Employer Identification No.) |
(Address of principal executive offices) (Zip Code)
(
(Registrant's telephone number, including area code)
Not
Applicable
(Former name, former address and former fiscal year, if changed since last report date)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| Securities registered pursuant to Section 12(b) of the Act: | ||
| Title of each class | Ticker symbol(s) | Name of each exchange on which registered |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Emerging
growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
| Item 2.02 | Results of Operations and Financial Condition |
On November 10, 2026, Precipio, Inc. (the “Company”) issued a press release announcing its financial results for the second quarter that ended September 30, 2026. A copy of the press release is being furnished as Exhibit 99.1 to this Report on Form 8-K.
The information in this contained in Item 2.02 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
| Item 9.01 | Financial Statements and Exhibits |
(d) Exhibits
| 99.1 | Press Release issued by Precipio Inc. on November 10, 2026, furnished herewith. |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| PRECIPIO, INC. | ||
| By: | /s/ Ilan Danieli | |
| Name: | Ilan Danieli | |
| Title: | Chief Executive Officer | |
Date: November 10, 2026
Exhibit 99.1
Precipio Announces Q3-2026 Financial Results
Record quarterly revenue, positive Adjusted EBITDA, and strong operating cash flow - all position Precipio for accelerated future growth
NEW HAVEN, CT, Globenewswire – (Nov 10, 2026) - Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces third-quarter financial results for the quarter ending September 30, 2026.
Below are some of the key financial performance metrics for the Company. For additional results, please see the Company’s Form 10-Q filed today.
| ● | Revenue – $7.3M, up 8% year-over-year from $6.8M in Q3-2025 and from $7.0M in Q2-2026. This comprises $1.0M in product revenue (up 40% year-over-year from $0.7M in Q3-2025, and $0.9M in Q2-2026), and $6.3M in pathology revenue (up 5% year-over-year from $6.0M in Q3-2025, and $6.1M in Q2-2026). |
| ● | Adjusted EBITDA – $0.4M vs. $0.5M in Q3-2025 and $0.4M in Q2-2026. |
| ● | Cash flow - Cash flow from operations was $0.6M in Q3-2026; total cash increased by $0.5M, resulting in an end-of-quarter cash balance exceeding $3.5M, vs $2.3M in Q3-2025. |
“In the third quarter we continued to strengthen our financial position, delivering record revenue while maintaining positive Adjusted EBITDA and generating cash from operations,” said Ilan Danieli, CEO of Precipio. “Our pathology business continues to provide a strong operational and financial foundation for growth, while also serving as the clinical development and validation platform for our proprietary diagnostic products. With more than $3.5 million in cash at quarter-end, we believe we are well positioned to accelerate commercialization of our existing product portfolio and pursue the significant longer-term growth opportunities ahead of us.”
Additional information and a more in-depth discussion on the Company’s Q3-2026 performance will be provided in the shareholder call today at 5 PM ET. The call will include remarks by management on the Company’s core business, followed by a moderated Q&A session.
EBITDA and Adjusted EBITDA Reconciliation and Explanation
EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is a non-GAAP financial measure that is widely used to evaluate operational performance and pre-tax profitability of emerging growth companies like ours. Management believes Adjusted EBITDA provides investors with a useful perspective on the Company’s financial performance, particularly where non-cash amortization has an important impact on profitability.
Adjusted EBITDA as we define it modifies EBITDA by excluding the non-cash costs of employee stock options and unusual non-operating income and expense. Below is a reconciliation of Net Income, EBITDA and Adjusted EBITDA for the third quarter of 2026 and 2025:
| ($ in millions, unaudited) | Q3-26 | Q3-25 | ||||||
| Net income/(loss) (GAAP) | $ | 0.0 | $ | (0.1 | ) | |||
| Adjustments to net income/(loss): | ||||||||
| Interest expense, net | $ | 0.0 | $ | 0.0 | ||||
| Income taxes | $ | 0.0 | $ | 0.0 | ||||
| Depreciation | $ | 0.1 | $ | 0.1 | ||||
| Amortization of intangibles | $ | 0.2 | $ | 0.3 | ||||
| EBITDA (non-GAAP) | $ | 0.3 | $ | 0.3 | ||||
| Further Adjustments to EBITDA | ||||||||
| Stock-based compensation expense | $ | 0.1 | $ | 0.2 | ||||
| Other significant (income) expenses | $ | 0.0 | $ | 0.0 | ||||
| Adjusted EBITDA (non-GAAP) | $ | 0.4 | $ | 0.5 | ||||
About Precipio
Precipio is a healthcare biotechnology company focused on cancer diagnostics. Our mission is to address the pervasive problem of cancer misdiagnoses by developing solutions in the form of diagnostic products and services. Our products and services deliver higher accuracy, improved laboratory workflow, and ultimately better patient outcomes, which reduce healthcare expenses. Precipio develops innovative technologies in our laboratory where we design, test, validate, and use these products clinically, improving diagnostic outcomes. Precipio then commercializes these technologies as proprietary products that serve the global laboratory community and further scale Precipio’s reach to eradicate misdiagnosis.
Availability of Other Information About Precipio
For more information, please visit the Precipio website at https://www.precipiodx.com/ or follow Precipio on X (formerly Twitter) (@PrecipioDx) and LinkedIn (Precipio) and on Facebook. Investors and others should note that we communicate with our investors and the public using our company website (https://www.precipiodx.com), including, but not limited to, company disclosures, investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference call transcripts and webcast transcripts, as well as on X and LinkedIn. The information that we post on our website or on X or LinkedIn could be deemed to be material information. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. The contents of our website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding the targets set herein and related timing. Except for historical information, statements about future volumes, sales, growth, costs, cost savings, margins, earnings, earnings per share, diluted earnings per share, cash flows, adjusted EBITDA, plans, objectives, expectations, growth or profitability and our potential to reach financial independence are forward-looking statements based on management’s estimates, beliefs, assumptions and projections. Words such as “could,” “may,” “expects,” “anticipates,” “will,” “targets,” “goals,” “projects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “predicts,” and variations on such words, and similar expressions that reflect our current views with respect to future events and operational, economic and financial performance, are intended to identify such forward-looking statements. These forward-looking statements are only predictions based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the important factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025, and our other reports filed with the U.S. Securities and Exchange Commission. Any such forward-looking statements represent management’s estimates as of the date of this press release only. While we may elect to update such forward-looking statements at some point in the future, except as required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.
Inquiries:
investors@precipiodx.com
+1-203-787-7888 Ext. 523